Drug Makers Settle Suit Over Epilepsy Treatment

Law360, New York (July 2, 2007, 12:00 AM EDT) -- Kali Laboratories Inc. will not be able to introduce a generic version of a Valeant Pharmaceuticals International epileptic seizure treatment for more than three years under a patent infringement settlement announced Monday.

Under the agreement, Kali may not introduce a generic version of Diastate and Diastate AcuDial until September 2010. Other terms of the settlement, which was reached last week at a conference in a New Jersey court, were not disclosed. The companies have 60 days to finalize the agreement.

Xcel Pharmaceuticals, which was acquired by...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.